查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球生物模拟市场：增长、未来展望、竞争分析 (2022-2030)
市场调查报告书
商品编码
1166626

全球生物模拟市场：增长、未来展望、竞争分析 (2022-2030)

Biosimulation Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 120 Pages | 商品交期: 最快1-2个工作天内

价格

从应用领域来看，全球生物模拟市场中，药物研发领域占比较大。 这部分是由于越来越需要减少与目前用于治疗的药物相关的副作用。 此外，药物开发中基于计算机的建模成功率的显着提高导致需求增加。 由于人们越来越认识到生物模拟的好处，例如缩小阻碍药物发现过程的差距，这反过来又降低了药物发现的失败率，预计药物发现领域在预测期内也将增长。

按地区划分，北美所占份额最大。 关键因素包括药物开发启动的增加、严格的监管政策、临床试验前对预分析的需求增加，以及製药公司/研究机构与芯片开发人员之间的战略合作伙伴关係增加。您可以 预计在 2022-2030 年的预测期内，亚太地区的生物模拟市场将呈现正增长。

在这份报告中，我们分析了全球生物模拟市场，包括市场的基本结构、宏观和微观环境因素、整体市场规模趋势展望（2020-2030），以及按类型和应用划分。□我们将彙编和发布信息，例如各地区的详细趋势、主要市场驱动因素和製约因素、主要公司的概况和增长战略。

内容

第一章介绍

第 2 章执行摘要

第 3 章生物模拟市场：竞争分析

  • 生物模拟市场：主要供应商的市场定位
  • 供应商在生物模拟市场采用的策略
  • 主要行业战略
  • 层次分析 (2021/2030)

第 4 章生物模拟市场：宏观分析和市场动态

  • 介绍
  • 全球生物模拟市场规模（单位：百万美元，2020-2030 年）
  • 市场动态
    • 市场驱动因素
    • 市场製约因素
    • 主要问题
    • 主要机会
  • 促进因素和抑制因素的影响分析
  • 跷跷板分析

第 5 章生物模拟市场：按类型（单位：百万美元，2020-2030）

  • 市场概览
  • 增长和收益分析 (2021/2030)
  • 市场细分
    • PK/PD 建模和仿真软件
    • 分子建模和模拟软件
    • PBPK 建模和仿真软件
    • 毒性预测软件
    • 临床试验设计软件
    • 其他软件

第 6 章生物模拟市场：按应用（单位：百万美元，2020-2030）

  • 市场概览
  • 增长和收益分析 (2021/2030)
  • 市场细分
    • 药物开发
    • 药物发现

第7章北美生物模拟市场（单位：百万美元，2020-2030）

  • 市场概览
  • 生物模拟市场：按类型分类（单位：百万美元，2020-2030 年）
  • 生物模拟市场：按应用分类（单位：百万美元，2020-2030 年）
  • 生物模拟市场：按地区（单位：百万美元，2020-2030 年）
    • 北美

第8章英国和欧盟国家的生物模拟市场（单位：百万美元，2020-2030）

第9章亚太生物模拟市场（单位：百万美元，2020-2030）

第十章拉丁美洲生物模拟市场（单位：百万美元，2020-2030）

第 11 章中东和非洲的生物模拟市场（单位：百万美元，2020-2030 年）

第12章公司简介

  • Medtronic
  • Certara USA, Inc.
  • Simulation Plus, Inc.
  • Dassault Systems SA
  • Schrodinger, Inc.
  • Advanced Chemistry Development, Inc.
  • Chemical Computing Group, Inc.
  • Physiomics PLC
  • Entelos, Inc.
  • Rhenovia Pharma Ltd.
  • Genedata AG
  • Evidera, Inc.
  • In Silico Biosciences Inc.
  • Oxford Drug Design
  • Insilico Biotechnology AG
  • Leadinvent technologies Pvt Ltd.
  • Leadscope, Inc.
Product Code: 137792-08-22

The report titled "Global Biosimulation Market: Growth, Future Prospects, and Competitive Analysis, 2022 -2030" offers strategic insights into the overall biosimulation market along with the market size and estimates for the duration of 2020 to 2030. The said research study covers in-depth analysis of biosimulation market segments based on software type, application and different geographies further segmented by countries. Biosimulation techniques are the newest additions to the drug development industry which is based on simulation of biologic process via computer programs. This technique is widely used to predict the path of drug development and has proven beneficial in reducing patient numbers, time and cost incurred in the entire drug development process, thus proving beneficial for the pharmaceutical industries for its overall growth. Owing to the aforementioned benefits and an increase in awareness, demand and adoption of biosimulation, this market is presumed to have an increased growth in the forecasted period of 2022-2030.

Market size estimates and forecast for these segments for the period 2020 to 2030 are provided in terms of US$ Mn along with the respective compounded annual growth rates (CAGRs) for the period 2022 to 2030, considering 2021 as the base year.

The geographical segmentation of the global biosimulation market comprised regions such as North America, Europe, Asia-Pacific, Latin America & Middle East and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries. Market size and forecast for these segments during 2020 to 2030 and their CAGRs for the period 2022 to 2030 are provided in this report.

The biosimulation market is observed as the most diversified and competitive market comprising large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Certara USA, Inc., Simulation Plus, Inc., Dassault Systems SA, Schrodinger, Inc., Advanced Chemistry Development, Inc., Chemical Computing Group, Inc., Physiomics PLC, Entelos, Inc., Rhenovia Pharma Ltd., Genedata AG, Evidera, Inc., In Silico Biosciences Inc., Oxford Drug Design, Insilico Biotechnology AG, Leadinvent technologies Pvt Ltd. & Leadscope, Inc.

Within this segment showcases a highly consolidated market share, as each and every software would be used during the course of drug development. Each modeling and simulation software are essential in predicting each step of drug development. These software's would determine the course of a clinical trial and assess its success rate. Comparatively the PK/PD modeling and simulation software, molecular modeling and simulation software have a marginally higher market share owing to its majorly used applications such as dosage designing before a clinical trial, pharmacokinetic profiling of a drug or the success rate of drug administration on treatment outcome.

The drug development segment encapsulates a larger share in the biosimulation market. This dominance is attributed due to increase in need for reduction in adverse effects associated with the current drugs available for treatment, which is propelling the demand for in silico systems to aid in development of improved molecules. The increased demand is also due to significant increase in success rates of computer based modeling in drug development. The drug discovery segment is also expected to grow in the forecast period of 2022-2030 owing to growing awareness of benefits of biosimulation such as bridging the gaps that hinder the drug discovery process which would enable lowering the drug failure rates. The demand for biosimulation in drug discovery would also rise in the forecast period as there would be an increased demand for personalized medicines which would require lead/target identification and optimization.

Biosimulation provides simulation of biological system thus rendering most beneficial in the clinical trial development thus preventing the risks of drug failures. For the purpose of this study, the global biosimulation market is segmented into regional markets viz., North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Of the aforementioned regions, North America encapsulated the largest share in the biosimulation market. The major factors that drive this predominance in the North American market are increase in drug development initiations, stringent regulatory policies ensuring patient safety and efficacy standards thus raising the demand to pre-analyze the success rate of the molecule before entering clinical trials, rise in number of strategic collaborations between pharmaceutical industries/research institute and in silico developers for simulation based drug development. Asia-Pacific is projected to show a positive growth biosimulation market during the forecast period, 2022-2030. The drivers propelling this market are increasing presence of CRO's, development of healthcare infrastructure, penetration of healthcare IT and an extensive initiation of research and development activities.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Biosimulation market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Biosimulation market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Type

  • PK/PD Modeling and Simulation Software
  • Molecular Modeling and Simulation Software
  • PBPK Modeling and Simulation Software
  • Toxicity Prediction Software
  • Trial Design Software
  • Other Software's.

Application

  • Drug Development
  • Preclinical testing
  • Clinical trials
  • Drug Discovery

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Biosimulation market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Biosimulation market?
  • Which is the largest regional market for Biosimulation market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Biosimulation market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Biosimulation market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Biosimulation Market
  • 2.2. Global Biosimulation Market, By Type, 2021 (US$ Million)
  • 2.3. Global Biosimulation Market, By Application, 2021 (US$ Million)
  • 2.4. Global Biosimulation Market, By Geography, 2021 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2021

3. Biosimulation Market: Competitive Analysis

  • 3.1. Market Positioning of Key Biosimulation Market Vendors
  • 3.2. Strategies Adopted by Biosimulation Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Biosimulation Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Biosimulation Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Biosimulation Market: By Type, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. PK/PD Modeling and Simulation Software
    • 5.3.2. Molecular Modeling and Simulation Software
    • 5.3.3. PBPK Modeling and Simulation Software
    • 5.3.4. Toxicity Prediction Software
    • 5.3.5. Trial Design Software
    • 5.3.6. Other Software's.

6. Biosimulation Market: By Application, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 6.3. Market Segmentation
    • 6.3.1. Drug Development
      • 6.3.1.1. Preclinical testing
      • 6.3.1.2. Clinical trials
    • 6.3.2. Drug Discovery

7. North America Biosimulation Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Biosimulation Market: By Type, 2020-2030, USD (Million)
  • 7.3. Biosimulation Market: By Application, 2020-2030, USD (Million)
  • 7.4.Biosimulation Market: By Region, 2020-2030, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 7.4.1.1.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 7.4.1.2.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 7.4.1.3.1. Biosimulation Market: By Application, 2020-2030, USD (Million)

8. UK and European Union Biosimulation Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Biosimulation Market: By Type, 2020-2030, USD (Million)
  • 8.3. Biosimulation Market: By Application, 2020-2030, USD (Million)
  • 8.4.Biosimulation Market: By Region, 2020-2030, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 8.4.1.1.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 8.4.1.2.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 8.4.1.3.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 8.4.1.4.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 8.4.1.5.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 8.4.1.6.1. Biosimulation Market: By Application, 2020-2030, USD (Million)

9. Asia Pacific Biosimulation Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Biosimulation Market: By Type, 2020-2030, USD (Million)
  • 9.3. Biosimulation Market: By Application, 2020-2030, USD (Million)
  • 9.4.Biosimulation Market: By Region, 2020-2030, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 9.4.1.1.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 9.4.1.2.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 9.4.1.3.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 9.4.1.4.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 9.4.1.5.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 9.4.1.6.1. Biosimulation Market: By Application, 2020-2030, USD (Million)

10. Latin America Biosimulation Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Biosimulation Market: By Type, 2020-2030, USD (Million)
  • 10.3. Biosimulation Market: By Application, 2020-2030, USD (Million)
  • 10.4.Biosimulation Market: By Region, 2020-2030, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 10.4.1.1.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 10.4.1.2.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 10.4.1.3.1. Biosimulation Market: By Application, 2020-2030, USD (Million)

11. Middle East and Africa Biosimulation Market, 2020-2030, USD (Million)

  • 11.1. Market Overview
  • 11.2. Biosimulation Market: By Type, 2020-2030, USD (Million)
  • 11.3. Biosimulation Market: By Application, 2020-2030, USD (Million)
  • 11.4.Biosimulation Market: By Region, 2020-2030, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 11.4.1.1.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 11.4.1.2.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 11.4.1.3.1. Biosimulation Market: By Application, 2020-2030, USD (Million)

12. Company Profile

  • 12.1. Medtronic
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Certara USA, Inc.
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Simulation Plus, Inc.
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Dassault Systems SA
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Schrodinger, Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Advanced Chemistry Development, Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Chemical Computing Group, Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Physiomics PLC
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Entelos, Inc.
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Rhenovia Pharma Ltd.
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Genedata AG
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives
  • 12.12. Evidera, Inc.
    • 12.12.1. Company Overview
    • 12.12.2. Financial Performance
    • 12.12.3. Product Portfolio
    • 12.12.4. Strategic Initiatives
  • 12.13. In Silico Biosciences Inc.
    • 12.13.1. Company Overview
    • 12.13.2. Financial Performance
    • 12.13.3. Product Portfolio
    • 12.13.4. Strategic Initiatives
  • 12.14. Oxford Drug Design
    • 12.14.1. Company Overview
    • 12.14.2. Financial Performance
    • 12.14.3. Product Portfolio
    • 12.14.4. Strategic Initiatives
  • 12.15. Insilico Biotechnology AG
    • 12.15.1. Company Overview
    • 12.15.2. Financial Performance
    • 12.15.3. Product Portfolio
    • 12.15.4. Strategic Initiatives
  • 12.16. Leadinvent technologies Pvt Ltd.
    • 12.16.1. Company Overview
    • 12.16.2. Financial Performance
    • 12.16.3. Product Portfolio
    • 12.16.4. Strategic Initiatives
  • 12.17. Leadscope, Inc.
    • 12.17.1. Company Overview
    • 12.17.2. Financial Performance
    • 12.17.3. Product Portfolio
    • 12.17.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 2 Global Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 3 Global Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 4 North America Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 5 North America Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 6 North America Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 7 U.S. Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 8 U.S. Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 9 U.S. Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 10 Canada Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 11 Canada Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 12 Canada Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 13 Rest of North America Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 14 Rest of North America Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 15 Rest of North America Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 16 UK and European Union Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 17 UK and European Union Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 18 UK and European Union Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 19 UK Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 20 UK Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 21 UK Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 22 Germany Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 23 Germany Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 24 Germany Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 25 Spain Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 26 Spain Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 27 Spain Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 28 Italy Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 29 Italy Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 30 Italy Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 31 France Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 32 France Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 33 France Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 34 Rest of Europe Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 35 Rest of Europe Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 36 Rest of Europe Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 37 Asia Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 38 Asia Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 39 Asia Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 40 China Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 41 China Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 42 China Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 43 Japan Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 44 Japan Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 45 Japan Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 46 India Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 47 India Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 48 India Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 49 Australia Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 50 Australia Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 51 Australia Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 52 South Korea Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 53 South Korea Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 54 South Korea Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 55 Latin America Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 56 Latin America Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 57 Latin America Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 58 Brazil Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 59 Brazil Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 60 Brazil Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 61 Mexico Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 62 Mexico Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 63 Mexico Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 64 Rest of Latin America Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 65 Rest of Latin America Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 66 Rest of Latin America Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 67 Middle East and Africa Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 68 Middle East and Africa Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 69 Middle East and Africa Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 70 GCC Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 71 GCC Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 72 GCC Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 73 Africa Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 74 Africa Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 75 Africa Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 76 Rest of Middle East and Africa Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 77 Rest of Middle East and Africa Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 78 Rest of Middle East and Africa Biosimulation Market By Drug Development, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Biosimulation Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Biosimulation Market: Quality Assurance
  • FIG. 5 Global Biosimulation Market, By Type, 2021
  • FIG. 6 Global Biosimulation Market, By Application, 2021
  • FIG. 7 Global Biosimulation Market, By Geography, 2021
  • FIG. 8 Market Geographical Opportunity Matrix - Global Biosimulation Market, 2021
  • FIG. 9 Market Positioning of Key Biosimulation Market Players, 2021
  • FIG. 10 Global Biosimulation Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 11 Global Biosimulation Market, By Type, 2021 Vs 2030, %
  • FIG. 12 Global Biosimulation Market, By Application, 2021 Vs 2030, %
  • FIG. 13 U.S. Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 14 Canada Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 15 Rest of North America Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 16 UK Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 17 Germany Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 18 Spain Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 19 Italy Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 20 France Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 21 Rest of Europe Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 22 China Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 23 Japan Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 24 India Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 25 Australia Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 26 South Korea Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 27 Rest of Asia Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 28 Brazil Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 29 Mexico Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 30 Rest of Latin America Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 31 GCC Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 32 Africa Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 33 Rest of Middle East and Africa Biosimulation Market (US$ Million), 2020 - 2030